1. Home
  2. HROW
  3. HROW News

Latest Harrow Inc. (HROW) News on November 8, 2025

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025
HROW

GlobeNewswire

12 days ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

HROW

MT Newswires

a month ago

B. Riley Adjusts Price Target on Harrow to $74 From $70, Maintains Buy Rating

Harrow (HROW) Launches US$250M Senior Notes Offering To Refinance Debt
HROW

Simply Wall St.

2 months ago

Harrow (HROW) Launches US$250M Senior Notes Offering To Refinance Debt

Insider-Favored Growth Stocks For September 2025
HROW

Simply Wall St.

2 months ago

Insider-Favored Growth Stocks For September 2025

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
HROW

GlobeNewswire

2 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

HROW

MT Newswires

2 months ago

Harrow Launches $250 Million Private Offering of Senior Notes Due 2030; Shares Up Pre-Bell

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
HROW

GlobeNewswire

2 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

We Might See A Profit From Harrow, Inc. (NASDAQ:HROW) Soon
HROW

Simply Wall St.

4 months ago

We Might See A Profit From Harrow, Inc. (NASDAQ:HROW) Soon

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
HROW

Business Wire

5 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
HROW

Business Wire

5 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Insiders Favor Harrow And 2 Other Leading Growth Companies
HROW

Simply Wall St.

5 months ago

Insiders Favor Harrow And 2 Other Leading Growth Companies

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”
HROW

Insider Monkey

6 months ago

Jim Cramer on Harrow, Inc. (HROW) – “Eye Care’s a Good Biz – If It Makes Money, Don’t Walk Away Pre-Breakout”

Harrow to Present at Two Investor Conferences in May
HROW

Business Wire

6 months ago

Harrow to Present at Two Investor Conferences in May

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...
HROW

GuruFocus.com

6 months ago

Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ...

Harrow Announces First-Quarter 2025 Financial Results
HROW

Business Wire

6 months ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For
HROW

GuruFocus.com

6 months ago

Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings
HROW

GuruFocus.com

6 months ago

What To Expect From Harrow Inc (HROW) Q1 2025 Earnings

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025
HROW

Business Wire

6 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

3 Growth Stocks Insiders Are Betting On
HROW

Simply Wall St.

6 months ago

3 Growth Stocks Insiders Are Betting On

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
HROW

PR Newswire

6 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
HROW

GuruFocus.com

7 months ago

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
HROW

Business Wire

7 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives
HROW

GuruFocus.com

7 months ago

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
HROW

Business Wire

7 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
HROW

Business Wire

7 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow And 2 Insider Picks For Growth Potential
HROW

Simply Wall St.

7 months ago

Harrow And 2 Insider Picks For Growth Potential

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
HROW

Business Wire

7 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings
HROW

GuruFocus.com

8 months ago

What To Expect From Harrow Inc (HROW) Q4 2024 Earnings

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
HROW

Business Wire

8 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All
HROW

Business Wire

8 months ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
HROW

Business Wire

8 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
HROW

Business Wire

8 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

US Growth Companies With High Insider Ownership To Watch
HROW

Simply Wall St.

8 months ago

US Growth Companies With High Insider Ownership To Watch

Harrow (NASDAQ:HROW) shareholders have earned a 40% CAGR over the last five years
HROW

Simply Wall St.

9 months ago

Harrow (NASDAQ:HROW) shareholders have earned a 40% CAGR over the last five years

Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls
HROW

TipRanks

9 months ago

Reddit initiated, Cigna downgraded: Wall Street’s top analyst calls

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
HROW

Business Wire

9 months ago

Harrow Partners with Cencora to Launch "Harrow Cares" Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

3 US Growth Companies With High Insider Ownership Seeing Up To 39% Revenue Growth
HROW

Simply Wall St.

10 months ago

3 US Growth Companies With High Insider Ownership Seeing Up To 39% Revenue Growth

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
HROW

Business Wire

10 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth
HROW

Simply Wall St.

10 months ago

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

US Growth Stocks With High Insider Ownership To Watch
HROW

Simply Wall St.

a year ago

US Growth Stocks With High Insider Ownership To Watch

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
HROW

Business Wire

a year ago

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
HROW

Business Wire

a year ago

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Harrow Announces Participation in Upcoming Investor Conferences
HROW

Business Wire

a year ago

Harrow Announces Participation in Upcoming Investor Conferences

Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...
HROW

GuruFocus.com

a year ago

Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...

Harrow Announces Third Quarter 2024 Financial Results
HROW

Business Wire

a year ago

Harrow Announces Third Quarter 2024 Financial Results

Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For
HROW

GuruFocus.com

a year ago

Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
HROW

Business Wire

a year ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Harrow Announces Market Access Wins for VEVYE®
HROW

Business Wire

a year ago

Harrow Announces Market Access Wins for VEVYE®

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
HROW

Business Wire

a year ago

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
HROW

Business Wire

a year ago

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

3 US Growth Stocks With High Insider Ownership And 167% Earnings Growth
HROW

Simply Wall St.

a year ago

3 US Growth Stocks With High Insider Ownership And 167% Earnings Growth

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
HROW

Business Wire

a year ago

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Harrow Relaunches TRIESENCE®
HROW

Business Wire

a year ago

Harrow Relaunches TRIESENCE®

Harrow, Inc. (HROW): A Bull Case Theory
HROW

Insider Monkey

a year ago

Harrow, Inc. (HROW): A Bull Case Theory

Harrow Announces Nashville Expansion
HROW

Business Wire

a year ago

Harrow Announces Nashville Expansion

Three US Growth Companies With High Insider Ownership
HROW

Simply Wall St.

a year ago

Three US Growth Companies With High Insider Ownership

Harrow to Present at Three Investor Conferences in September in New York
HROW

Business Wire

a year ago

Harrow to Present at Three Investor Conferences in September in New York

Harrow Announces Second Quarter 2024 Financial Results
HROW

Business Wire

a year ago

Harrow Announces Second Quarter 2024 Financial Results

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
HROW

Business Wire

a year ago

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Harrow to Attend 2024 ASRS Annual Meeting
HROW

Business Wire

a year ago

Harrow to Attend 2024 ASRS Annual Meeting

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
HROW

Business Wire

a year ago

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Harrow Provides TRIESENCE® Relaunch Update
HROW

Business Wire

a year ago

Harrow Provides TRIESENCE® Relaunch Update

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
HROW

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
HROW

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
HROW

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
HROW

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
HROW

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
HROW

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
HROW

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
HROW

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
HROW

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller
HROW

AFP

a year ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up
HROW

AFP

a year ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally
HROW

AFP

a year ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
HROW

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
HROW

Business Wire

a year ago

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
HROW

Business Wire

a year ago

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

Harrow to Present at Two Investor Conferences in May
HROW

Business Wire

a year ago

Harrow to Present at Two Investor Conferences in May

HROW

MT Newswires

a year ago

Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours

Harrow Announces First Quarter 2024 Financial Results
HROW

Business Wire

a year ago

Harrow Announces First Quarter 2024 Financial Results

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
HROW

Business Wire

a year ago

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
HROW

Business Wire

2 years ago

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
HROW

Business Wire

2 years ago

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript
HROW

Insider Monkey

2 years ago

Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript

Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023
HROW

GuruFocus.com

2 years ago

Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
HROW

Business Wire

2 years ago

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

Harrow (HROW) Fell on Lowering the Guidance
HROW

Insider Monkey

2 years ago

Harrow (HROW) Fell on Lowering the Guidance

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
HROW

Business Wire

2 years ago

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

Here’s How Harrow (HROW) Weighed on SRK Capital’s Performance
HROW

Insider Monkey

2 years ago

Here’s How Harrow (HROW) Weighed on SRK Capital’s Performance

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
HROW

Business Wire

2 years ago

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

HROW

Business Wire

2 years ago

Early Repurchase(s)

Yacktman Asset Management Adjusts Portfolio, Weatherford International PLC Sees Significant ...
HROW

GuruFocus.com

2 years ago

Yacktman Asset Management Adjusts Portfolio, Weatherford International PLC Sees Significant ...

HROW

Associated Press Finance

2 years ago

BrightView: Fiscal Q1 Earnings Snapshot

BrightView Reports First Quarter Fiscal 2024 Results, Reaffirms 2024 Guidance and Announces Sale of Non-Core Business
HROW

Business Wire

2 years ago

BrightView Reports First Quarter Fiscal 2024 Results, Reaffirms 2024 Guidance and Announces Sale of Non-Core Business

Harrow Announces New Appointments to its Board of Directors
HROW

Business Wire

2 years ago

Harrow Announces New Appointments to its Board of Directors

REGISTER | WEBINAR INVITATION: Capital Link’s 2024 Virtual Corporate Presentation Series
HROW

GlobeNewswire

2 years ago

REGISTER | WEBINAR INVITATION: Capital Link’s 2024 Virtual Corporate Presentation Series

BrightView Publishes 2024 Corporate Responsibility Report
HROW

Business Wire

2 years ago

BrightView Publishes 2024 Corporate Responsibility Report

Equity Commonwealth Announces Tax Treatment of 2023 Distributions
HROW

Business Wire

2 years ago

Equity Commonwealth Announces Tax Treatment of 2023 Distributions

Footwear Retailer Stocks Q3 Highlights: Shoe Carnival (NASDAQ:SCVL)
HROW

StockStory

2 years ago

Footwear Retailer Stocks Q3 Highlights: Shoe Carnival (NASDAQ:SCVL)

Old Second Bancorp, Inc. Reports Fourth Quarter 2023 Net Income of $18.2 Million, or $0.40 per Diluted Share
HROW

ACCESSWIRE

2 years ago

Old Second Bancorp, Inc. Reports Fourth Quarter 2023 Net Income of $18.2 Million, or $0.40 per Diluted Share

Share on Social Networks: